Navigation Links
BIO-key Reports Second Quarter 2007 Results
Date:9/3/2007

months of 2006.

Liquidity and Capital Resources

Consolidated cash and cash equivalents at June 30, 2007 was $0.6 million.

During the second quarter, BIO-key announced the sale of its Fire/EMS Services Division to ZOLL Data Systems for $7 million in cash. Approximately $4.3 million of the transaction's proceeds were used to repay all of the Company's senior secured debt obligations. Additionally, $0.4 million of the proceeds were placed in escrow pursuant to the Purchase Agreement, and are to be remitted to BIO-key under the terms of the agreement.

DePasquale concluded, "We believe the sale of our Fire/EMS Services businesses to ZOLL Data Systems is a confirmation of what we have been building over the last three years. We sold the unit -- which we viewed as a non-strategic asset -- for over two times what we paid as part of our acquisition of Aether Systems' Mobile Government Division business in 2004. We then applied the proceeds to effectively eliminate all of our senior secured debt obligations and are now positioned with a stronger balance sheet and improved liquidity. We are now better situated to evaluate growth opportunities that will benefit the company in the long-term and grow shareholder value."

Conference Call Details

BIO-key has scheduled a call for Wednesday, August 15th at 9:00 a.m. Eastern Time to discuss second quarter 2007 financial results. Dialing 303-262-2211 and asking for the BIO-key call at least 10 minutes prior to the start time can access the conference call live. The conference call will also be broadcast live over the Internet by logging onto http://www.bio-key.com. A telephonic replay of the conference call will be available through August 22, 2007 and may be accessed by dialing 303-590-3000 and using the pass code 11095677#. Additionally, an archive of the webcast will be available shortly after completion of the call on the Company's website ('/>"/>

SOURCE BIO-key International, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology news :

1. Tulane researcher reports on origin of deadly fever outbreak
2. Many cats unaffected by catnip, C&EN reports
3. Breast implants not associated with cancer risk, study reports
4. Arsenic in chicken feed may pose health risks to humans, C&EN reports
5. New study reports hotel guests at risk from carbon monoxide poisoning
6. Researchers discover molecule that causes secondary stroke
7. Important discovery about second most fatal cancer
8. Second messenger NAADP shows fast, dose-related impact on satiety cycle
9. Female volunteers prepare for a second bedrest
10. Overbearing colored light may reveal a second mechanism by which birds interpret magnetic signals
11. Nanosecond-scale release of stinging jellyfish nematocysts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... new studies shed light on the complex defense mechanisms ... of which could lead to new, more effective antibiotics ... of antibiotic resistance. The studies, both of which target ... will appear in the February 17 inaugural print issue ...
... San Francisco, is just one of the many American ... trial in India. , The trial is studying ... Under Guidance): a reversible, nonhormonal contraceptive that provides 10 ... procedure. Researchers received approval this week to begin enrolling ...
... at just four months old, babies are able to ... according to brightness, shape, and how close the visual ... very young infants are much more capable of organising ... The study also has implications for understanding certain developmental ...
Cached Biology News:Pair of studies offer new clues to combat antibiotic resistance 2New male contraceptive clears hurdle 2New male contraceptive clears hurdle 3Infants can organise visual information at just four months 2Infants can organise visual information at just four months 3
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... 18, 2014 Egenix, Inc. is pleased to announce ... of the Board, to succeed Donald Fresne ; Mr. ... continue as a member of the Board.  In recognition of ... the company over almost twenty years, the Board designated Mr. ... Directors has established a Search Committee to find a suitable ...
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... 16 CEL-SCI Corporation (NYSE Amex: ... prevention and treatment of infectious diseases and a late-stage oncology ... (FDA) has indicated that the Company can proceed with its ... LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 ...
... , , EAST BRUNSWICK, N.J. Sept. 16 ... on September 14, 2009, the Company completed a Type A meeting with ... Letter (CRL) received by Savient on July 31, 2009 regarding the Company,s ... gout in patients refractory to conventional therapy. , ...
... ... FDA, including increased scrutiny of complex medical devices, automating your QA process is more ... one of the leading medical device software engineering and QA consulting firms in the ... , ...
Cached Biology Technology:CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 2CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 3CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 2Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 3Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 4Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 5Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM) 6Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
CCNI Antibody...
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Biology Products: